71450 Federal Register / Vol. 75, No. 225 / Tuesday, November 23, 2010 / Notices 

National Institutes of Health/NIAID, 6700B 

Rockledge Drive, MSC 7616, Bethesda, MD 

20892–7616. 301–496–2550. 

qvos@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: November 17, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–29525 Filed 11–22–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel 

Institutional National Research Service 

Awards. 

Date: December 15, 2010. 

Time: 1 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20817. 

(Virtual Meeting). 

Contact Person: Roy L White, PhD, 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7176, Bethesda, MD 20892–7924. 301–435– 

0310. whiterl@nhlbi.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel 

Conference Grants. 

Date: December 16–17, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

(Virtual Meeting). 

Contact Person: William J Johnson, PhD, 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7178, Bethesda, MD 20892–7924. 301–435– 

0725. johnsonwj@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: November 17, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–29524 Filed 11–22–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Oncologic Drugs Advisory Committee; 

Amendment of Notice 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing an 

amendment to the notice of a meeting of 

the Oncologic Drugs Advisory 

Committee. This meeting was 

announced in the Federal Register of 

October 19, 2010 (75 FR 64314). The 

amendment is being made to reflect 

changes in the Date and Time, Agenda, 

and Procedure portions of the 

document. We also are postponing a 

session regarding biologics license 

application (BLA) 125377, with the 

proposed trade name Yervoy 

(ipilimumab), manufactured by BristolMyers Squibb Co. The proposed 

indication (use) for this product is for 

the treatment of advanced melanoma in 

patients who have received prior 

therapy. This portion of the meeting has 

been postponed due to the need to 

complete the review of additional data 

submitted by the applicant. Future 

meeting dates may be announced in the 

Federal Register. 

FOR FURTHER INFORMATION CONTACT: 

Nicole Vesely, Center for Drug 

Evaluation and Research, Food and 

Drug Administration, 10903 New 

Hampshire Ave., Bldg. 31, Rm. 2417, 

Silver Spring, MD 20993–0002, 301– 

796–9001, FAX: 301–847–8533, e-mail: 

Nicole.vesely@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138, 301–443–0572 in the 

Washington, DC area, code 301–451– 

2542. Please call the Information Line 

for up-to-date information on this 

meeting. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of October 19, 2010 (75 

FR 64314), FDA announced that a 

meeting of the Oncologic Drugs 

Advisory Committee would be held on 

December 2, 2010. On page 64314, in 

the first column, the Date and Time 

portion of the document is changed to 

read as follows: 

Date and Time: The meeting will be 

held on December 2, 2010, from 8 a.m. 

to 12:30 p.m. 

On page 64314, in the second column, 

the Agenda portion of the document is 

changed to read as follows: 

Agenda: On December 2, 2010, the 

committee will discuss new drug 

application (NDA) 022–405, with the 

proposed trade name Zictifa 

(vandetanib) Tablets, manufactured by 

iPR Pharmaceuticals, Inc., represented 

by AstraZeneca Pharmaceuticals LP 

(authorized U.S. agent). The proposed 

indication (use) for this product is for 

the treatment of patients with 

unresectable (non-operable) locally 

advanced or metastatic medullary 

thyroid cancer. 

On page 64314, in the second column, 

the third sentence in the Procedure 

portion of the document is changed to 

read as follows: 

Procedure: Oral presentations from 

the public will be scheduled between 

approximately 10:30 a.m. and 11:30 a.m. 

This notice is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app. 2) and 21 CFR part 14, 

relating to the advisory committees. 

Dated: November 17, 2010. 

Joanne Less, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–29522 Filed 11–22–10; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the Sleep 

Disorders Research Advisory Board. 

The meeting will be open to the 

public. Individuals who plan to attend 

and need special assistance should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Sleep Disorders 

Research Advisory Board. 

mstockstill on DSKH9S0YB1PROD with NOTICES